The Michael J. Fox Foundation for Parkinson's Research
  Research
  News & Events
  Funding Programs
  About
PD Online Research
Alzheimer Research Forum
  Current Papers
  ARF Recommends
  Research News
Gene overview of all published PD-association studies for LRRK2
Back Search Methods Disclaimer Credits
 Gene: LRRK2  (PARK8; ROCO2)  Entrez Gene    View on AlzGene
 Protein: leucine-rich repeat kinase 2  (dardarin)  ProteinLink
 Chromosome: 12   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 17 December 2012
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      PD Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result
 Caucasian
Biskup, 2005
 Overlaps with
Simon-Sanchez, 2009 (Germany)		 CL  97  (detail)  340
(42%)		C52
(-)		-680
(-)		-Negative
Biskup, 2005
 Overlaps with
Simon-Sanchez, 2009 (Germany)		 CL  6  (detail)  322
(-)		C--322
(-)		-Negative
Chung, 2010
 USA CL  65  (detail)  449
(35%)		-64.7
(23-88)		70.3
(44-90)		449
(35%)		71.8
(45-93)		Trend
Clark, 2006
 USA CL  11  (detail)  504
(40%)		C53.8
(-)		61.8 + 12.5
(-)		314
(43%)		66.5 + 11.4
(-)		Positive
Dupre, 2007
 Canada CL  6  (detail)  125
(29%)		C55.3
(30-79)		-95
(-)		-Negative
Fung, 2006
 Overlaps with
Simon-Sanchez, 2009 (USA)		 CL  59  (detail)  267
(-)		C--270
(-)		68
(55-88)		n.a.
Hamza, 2010
 USA (NGRC-GWAS) CL  6  (detail)  2000
(33%)		C58.3 + 11.9
(-)		67.2 + 10.6
(-)		1986
(61%)		70.3 + 14
(21-90)		Positive
IPDGC, 2011
 France (GWAS) CL,PO  1  (detail)  1039
(41%)		U48.9 + 48.9
(-)		-1984
(33%)		73.7 + 5.4
(-)		Positive
IPDGC, 2011
 France (REP-Immuno) CL  1  (detail)  267
(-)		U--363
(-)		-Positive
IPDGC, 2011
 Germany (REP-Immuno) CL  1  (detail)  1153
(-)		U--712
(-)		-Positive
IPDGC, 2011
 Iceland (REP-in silico) CL,PO  1  (detail)  479
(-)		C--1427
(-)		-Positive
IPDGC, 2011
 Netherlands (REP-in silico) CL,PO  1  (detail)  824
(-)		U--2082
(-)		-Positive
IPDGC, 2011
 UK (REP-Immuno) CL  1  (detail)  1271
(-)		U--1864
(-)		-Positive
IPDGC, 2011
 USA (PROGENI/GenePD-GWAS) CL  1  (detail)  876
(40%)		U61.5 + 61.5
(-)		-857
(60%)		-Positive
IPDGC, 2011
 USA (NINDS-GWAS) CL  1  (detail)  971
(40%)		U55.9 + 55.9
(-)		-3034
(53%)		62 + 15.6
(-)		Positive
IPDGC, 2011
 USA (REP-Immuno) CL  1  (detail)  2807
(-)		U--2215
(-)		-Positive
IPDGC, 2011
 Germany (GWAS) CL  1  (detail)  742
(40%)		U56 + 56
(-)		-944
(48%)		-Positive
IPDGC, 2011
 Netherlands (REP-Immuno) CL  1  (detail)  304
(-)		U--402
(-)		-Positive
IPDGC, 2011
 UK (WTCCC-GWAS) CL,PO  1  (detail)  1705
(43%)		U--5200
(50%)		-Positive
Lesage, 2009
 Mixed CL  1  (detail)  220
(-)		C--174
(-)		-Negative
Lu, 2008
 Netherlands CL  1  (detail)  106
(-)		C--96
(-)		-Positive
Maraganore, 2005
 USA CL  1  (detail)  332
(42%)		C63
(36-88)		68
(42-90)		332
(42%)		67
(42-91)		Negative
Nuytemans, 2009
 Belgium CL  16  (detail)  310
(42%)		C60.1 + 11.3
(-)		-363
(47%)		67 + 10
(-)		n.a.
Ozelius, 2006
 USA (Ashkenazi) CL  5  (detail)  120
(-)		C----Positive
Paisan-Ruiz, 2005
 Canada CL  4  (detail)  121
(40%)		C37.9 + 10.8
(14-65)		56.9 + 11.7
(33-83)		250
(59%)		73.3 + 8.5
(58-96)		Negative
Paisan-Ruiz, 2006
 Finland CL  36  (detail)  147
(41%)		C-67.2
(38-88)		136
(63%)		65.8
(37-87)		Negative
Paisan-Ruiz, 2006
 Greece CL  36  (detail)  217
(40%)		C63.3 + 9.6
(30-88)		69.8 + 8.7
(44-95)		221
(44%)		68.3 + 12.8
(32-93)		Negative
Paisan-Ruiz, 2008
 Overlaps with
Simon-Sanchez, 2009 (USA)		 CL  87  (detail)  272
(50%)		C--275
(52%)		68
(55-88)		Negative
Paisan-Ruiz, 2009
 Re-analysis of Fung, 2006 CL  0  ------n.a.
Pankratz, 2008
 USA (PROGENI, GenePD) CL  183  (detail)  857
(41%)		C61.9 + 10.8
(-)		-867
(60%)		54.8 + 13.1
(-)		Negative
Patra, 2008
 USA CL  6  (detail)  575
(42%)		C60.2
(22-82)		68
(-)		186
(61%)		62 + 14
(-)		Negative
Saad, 2010
 France (GWAS) CL  4  (detail)  1039
(41%)		C48.9 + 12.8
(-)		57.5 + 16.6
(-)		1984
(43%)		73.7 + 5.4
(-)		Trend
Simon-Sanchez, 2009
 USA, Germany, UK (Stage II) CL,PO  3  (detail)  3452
(32%)		M61.1
(-)		-4756
(39%)		-Positive
Simon-Sanchez, 2009
 USA, Germany (GWAS) CL,PO  50  (detail)  1745
(45%)		C55.8
(7-98)		-4047
(50%)		-Positive
Simon-Sanchez, 2009
 USA (NINDS-GWAS) CL  133  (detail)  931
(40%)		C--790
(58%)		-Positive
Simon-Sanchez, 2011
 Netherlands (GWAS) CL,PO  1  (detail)  772
(36%)		U55.3
(16-84)		62.3
(29-89)		2024
(56%)		53.7
(45-95)		Positive
Spencer, 2010
 UK (WTCCC2-GWAS) CL,PO  1  (detail)  1705
(-)		C--5175
(-)		-Negative
Sutherland, 2009
 Australia CL  24  (detail)  331
(51%)		C60.1 + 10.6
(-)		70.3 + 8.7
(-)		296
(51%)		70.5 + 8.9
(-)		Trend
Toft, 2007a
 Spain CL  1  (detail)  205
(-)		C-66 + 13
(-)		205
(-)		-Negative
Toft, 2007a
 Norway CL  1  (detail)  388
(-)		C-70 + 11
(-)		338
(-)		-Negative
Toft, 2007a
 Ireland CL  1  (detail)  186
(-)		C-61 + 13
(-)		186
(-)		-Negative
Toft, 2007b
 Norway CL  1  (detail)  433
(-)		C58 + 11
(25-88)		71 + 11
(43-97)		587
(-)		69 + 12
(41-104)		Negative
 African Descent
Ross, 2010
 USA CL  14  (detail)  22
(55%)		C50.6
(27-65)		58.7
(40-72)		92
(73%)		41.9
(20-71)		Negative
 Asian
An, 2008
 Overlaps with
Tan, 2010 (China)		 CL  1  (detail)  600
(41%)		C-55.9
(20-85)		334
(46%)		53.6 + 13.8
(24-91)		n.a.
Chan, 2008
 China CL  1  (detail)  82
(46%)		C56.9
(17-95)		63.8
(-)		31
(-)		70.4 + 9.2
(44-82)		Positive
Chang, 2011
 China CL  3  (detail)  636
(41%)		C55.8 + 11.1
(17-85)		-510
(43%)		52.4 + 14
(15-91)		Positive
Chen, 2010
 China CL  1  (detail)  430
(42%)		U-60.7 + 11.5
(17-90)		452
(41%)		59.2 + 9
(27-81)		Trend
Choi, 2008
 Korea CL  1  (detail)  72
(53%)		C38.8 + 7
(13-50)		-100
(-)		-Positive
Di Fonzo, 2006
 Taiwan CL  2  (detail)  608
(40%)		C54.9 + 11.9
(12-94)		66 + 12
(24-97)		373
(57%)		54.7 + 18.2
(11-87)		Positive
Farrer, 2007
 Overlaps with
Lin, 2010		 CL  1  (detail)  410
(43%)		C57.7
(-)		-335
(-)		-n.a.
Funayama, 2007
 Japan CL  1  (detail)  448
(52%)		C50.7 + 14.6
(5-89)		59.4 + 13.8
(15-93)		457
(47%)		43.8 + 16
(21-98)		Positive
Fung, 2006
 Taiwan CL  1  (detail)  305
(46%)		C61.8 + 10.6
(30-91)		-176
(46%)		59.6 + 9.6
(38-86)		Positive
Kim, 2009
 South Korea CL  2  (detail)  923
(56%)		C54.8 + 10.9
(18-85)		63.7 + 9.9
(22-91)		422
(55%)		61.9 + 9.5
(37-85)		Positive
Li, 2007
 China CL  1  (detail)  235
(43%)		C54.6 + 13.3
(14-88)		62.6 + 11.4
(15-88)		214
(43%)		52.9 + 11.7
(15-80)		Positive
Lin, 2010
 Overlaps with
Ross, 2008 (Taiwan)		 CL  6  (detail)  453
(43%)		C-57.9 + 11.7
(-)		291
(56%)		59.2 + 14.6
(-)		Positive
Lu, 2008
 Taiwan CL  4  (detail)  834
(41%)		C55.6 + 12.1
(12-94)		65.7 + 11.8
(24-97)		543
(59%)		51.9 + 18.4
(11-87)		Positive
Miyake, 2010
 Japan CL  1  (detail)  229
(62%)		C-68.4 + 8.7
(-)		358
(61%)		66.6 + 8.5
(-)		Positive
Pulkes, 2010
 Thailand CL  2  (detail)  154
(44%)		C61.2 + 9.8
(-)		-156
(-)		-Positive
Ross, 2008
 Overlaps with
Tan, 2006 (Singapore)		 CL  1  (detail)  250
(-)		C--250
(-)		-n.a.
Ross, 2008
 Taiwan (I) CL  1  (detail)  484
(-)		C--341
(-)		-Positive
Ross, 2008
 Taiwan (II) CL  1  (detail)  345
(-)		C--316
(-)		-Positive
Ross, 2008
 Japan CL  1  (detail)  151
(-)		C--95
(-)		-Negative
Satake, 2009
 Japan (Replication-2) CL  5  (detail)  321
(55%)		C63.7 + 9.7
(-)		-1614
(55%)		59.1 + 19.1
(-)		Positive
Satake, 2009
 Japan (Replication-1) CL  5  (detail)  612
(50%)		C43 + 13.8
(20-80)		-14139
(42%)		60.1 + 12.6
(-)		Positive
Satake, 2009
 Japan (GWAS) CL  5  (detail)  1078
(55%)		C-58.8 + 10.1
(22-88)		2628
(45%)		49.9 + 14.2
(-)		Positive
Seki, 2011
 Overlaps with
Funayama, 2007 (Japan)		 CL  1  (detail)  184
(-)		C--233
(-)		-n.a.
Skipper, 2005
 Singapore CL  6  (detail)  466
(44%)		C60 + 12
(24-81)		65 + 11
(30-91)		466
(44%)		60 + 11
(26-93)		Positive
Tan, 2006
 Singapore CL  1  (detail)  494
(44%)		C-64 + 11
(-)		495
(46%)		60 + 10
(-)		Positive
Tan, 2006b
 Overlaps with
Tan, 2006 (Singapore)		 CL  4  (detail)  141
(-)		---60
(-)		-n.a.
Tan, 2008a
 Overlaps with
Tan, 2006 (Singapore)		 CL  1  (detail)  204
(-)		-61.8 + 10
(-)		66.4 + 10.9
(-)		235
(-)		63.1 + 8.7
(-)		n.a.
Tan, 2008c
 Overlaps with
Tan, 2006 (Singapore)		 CL  1  (detail)  246
(44%)		C59 + 13
(30-88)		66 + 12
(32-95)		243
(46%)		62 + 10
(30-90)		n.a.
Tan, 2010
 China CL  5  (detail)  628
(41%)		C56
(16-85)		60
(15-86)		510
(63%)		56
(16-103)		Positive
Tan, 2010
 Overlaps with
Tan, 2006 (Singapore II)		 CL  8  (detail)  192
(43%)		C59
(31-73)		63
(36-74)		192
(53%)		64
(48-72)		Positive
Tan, 2010
 Overlaps with
Tan, 2006 (Singapore I)		 CL  15  (detail)  250
(47%)		C61
(29-88)		70
(32-90)		250
(52%)		66
(31-87)		Positive
Tan, 2010
 Overlaps with
Ross, 2008 (Taiwan I)		 CL  5  (detail)  293
(52%)		C53
(15-81)		62
(21-88)		299
(53%)		62
(22-87)		Positive
Tomiyama, 2008
 Japan CL  1  (detail)  501
(50%)		C58 + 10.5
(20-88)		65 + 9.6
(28-92)		583
(46%)		45 + 17
(21-98)		Negative
Wang, 2012
 China CL,PO  2  (detail)  2013
(39%)		C58.6 + 10.4
(-)		62.7 + 10.1
(-)		1971
(42%)		64.9 + 8.3
(-)		Positive
Wu, 2006
 China CL  1  (detail)  598
(38%)		C64.9 + 10.1
(37-84)		-765
(-)		65.4 + 13.2
(-)		Positive
Yao, 2011
 China CL  1  (detail)  401
(41%)		C54.8 + 11.2
(-)		-398
(47%)		53.4 + 13
(-)		Negative
Yu, 2009
 Overlaps with
Tan, 2010 (China)		 CL  1  (detail)  328
(46%)		C52.6 + 12.1
(-)		-300
(42%)		58.2 + 10.3
(-)		n.a.
Zabetian, 2009
 Japan, USA CL  3  (detail)  631
(58%)		C60.9
(17-89)		67.1
(22-91)		1641
(55%)		70.1
(37-101)		Positive
Zhang, 2009
 Overlaps with
Tan, 2010 (China)		 CL  1  (detail)  600
(41%)		C55.9 + 11.1
(20-85)		-459
(44%)		53.3 + 13.3
(17-91)		n.a.
Zheng, 2010
 China CL  1  (detail)  406
(44%)		C-60.7 + 11.9
(18-89)		412
(41%)		59.3 + 10.1
(27-81)		Positive
 Other/Mixed
Abdalla-Carvalho, 2010
 Brazil CL  1  (detail)  204
(35%)		C53.4 + 12.5
(-)		62 + 11.9
(-)		210
(-)		65.4 + 8.9
(-)		Negative
Jasinska-Myga, 2010
 Tunisia CL  18  (detail)  240
(52%)		C42 + 16
(20-82)		66 + 12
(27-87)		372
(49%)		58 + 11
(31-92)		Trend
Lesage, 2009
 Caribbean CL  1  (detail)  46
(-)		C--183
(-)		-Negative
Tan, 2007
 Singapore (Malay) CL  1  (detail)  98
(-)		C--173
(-)		-Negative
Tan, 2007
 Sinagapore (Indian) CL  1  (detail)  66
(-)		C--133
(-)		-Negative
Tan, 2008b
 Sinagapore (Indian) CL  1  (detail)  60
(-)		C--105
(-)		-Negative
Tan, 2008b
 Singapore (Malay) CL  1  (detail)  132
(-)		C--160
(-)		-Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result
 Caucasian
Chung, 2010
 USA  65  (detail)   654
(36%)		C60.4
(28-87)		66.3 + 30.8
(-)		654
(50%)		65.1
(32-90)		Trend
Maraganore, 2005
 USA  9  (detail)  443443
(39%)		C61
(31-94)		68
(33-96)		443
(52%)		66
(29-90)		Negative
Maraganore, 2005
 Overlaps with
Chung, 2010 (USA)		  24  (detail)  443443
(39%)		C61
(31-94)		68
(33-96)		443
(52%)		66
(29-90)		Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis ->  "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
PDGene Recent Updates
PDGene Top Results
*New* Top Results Details
1. MAPT/STH
2. SNCA
3. GBA
4. LRRK2
5. PM20D1
6. GAK
7. MCCC1
8. STK39
9. BST1
10. GPNMB   
[see more]
PDGene Stats
Studies: 881
Genes: 915
Polymorphisms: 3446
Meta-analyses: 889
PDGene Links
GEO-PD Meeting 2012
PDmutDB
Curated by the VIB Department of Molecular Genetics of the University of Antwerp
Parkinson's disease Mutation Database
Curated by Parkinson's Institute from Leiden University Medical Center
Mutation Database for Parkinson's Disease
Curated by the Institute for Infocomm Research in Singapore
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.
PD Online Research
Alzheimer Research Forum
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2013 Alzheimer Research Forum Disclaimer Copyright